Current stock page

Financial Data

KRYS Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

KRYSKrystal Biotech, Inc.

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 8/10
$305.23−$0.45 (−0.15%)

Latest quote

  • Momentum
    58
  • Value
    67
  • Quality
    83
  • Risk resilience
    69
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$127.34M$119.22M$116.36M$107.11M$97.8M$96.04M$88.18M$91.14M
Gross Profit$119.79M$112.79M$110.03M$96.19M$92.14M$88.88M$83.16M$86.19M
Operating Income$71.15M$58.42M$53.69M$44.44M$41.37M$39.31M$36.18M$41.38M
Net Income$63.07M$54.77M$55.93M$51.4M$79.37M$38.33M$35.73M$45.48M
EPS$2.13$1.85$1.91$1.77$2.74$1.33$1.24$1.58
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow$91.25M$74.79M$80.38M$77.51M$39.66M$52.73M$30.97M$52.84M
Capital Expenditure-$996K-$3.57M-$7.15M-$2.14M-$1.7M-$1.9M-$6.2M-$801K
Free Cash Flow$90.25M$71.22M$73.23M$75.37M$37.96M$50.83M$24.77M$52.04M
Net Cash Provided By Operating Activities$91.25M$74.79M$80.38M$77.51M$39.66M$52.73M$30.97M$52.84M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$1.59B$1.5B$1.4B$1.33B$1.24B$1.14B$1.07B$1.06B
Total Debt$8.59M$8.85M$9.11M$9.34M$9.51M$9.68M$9.66M$7.26M
Cash And Cash Equivalents$462.84M$427.74M$501.31M$496.3M$392.6M$353.83M$308.77M$344.87M
Total Liabilities$150.47M$141.52M$120.24M$114.23M$102.22M$97.75M$89.74M$109.46M
Total Stockholders Equity$1.44B$1.36B$1.28B$1.22B$1.14B$1.04B$984.67M$946.38M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio41.1239.6838.942.0929.6727.3633.6159.05
P/B ratio6.457.056.867.075.193.864.235.56
P/S ratio19.23———————
Debt To Equity0.010.010.010.010.010.010.010.01
Free Cash Flow Yield3.35%2.69%2.71%2.19%2.81%4.62%3.10%2.26%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio41.1239.6838.942.0929.6727.3633.6159.05
P/B ratio6.457.056.867.075.193.864.235.56
P/S ratio19.23———————
Return On Equity15.68%17.77%17.63%16.80%17.48%14.10%12.59%9.42%
Debt To Equity0.010.010.010.010.010.010.010.01

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe39.85x
Pb6.3x
Revenue Growth Yoy30.21%
EPS Growth Yoy-22.26%
Gross Margin93.36%
Operating Margin48.44%
ROE17.02%
ROIC13.70%
Debt To Equity0.01
FCF Yield3.43%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$305.23
Volume110,286
RSI (14)43.03
MACD-6.52
MACD signal-6.63
MACD histogram0.12
ADX (14)18.49
SMA (50)$326.77
SMA (200)$309.71
ATR (14)$11.13
Historical volatility (annualized)47.83%
Volume (20-day average)316,070

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score69/100
Beta0.74
Annual volatility39.38%
Max Drawdown-21.75%
Sharpe Ratio1.16
VaR (95%, 1-day)-3.50%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

KRYS Financial Data FAQ

What is Krystal Biotech, Inc.'s revenue?

Krystal Biotech, Inc.'s revenue is one of the core financial data points for KRYS. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Krystal Biotech, Inc.'s revenue growing?

Revenue growth shows whether Krystal Biotech, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is KRYS's EPS?

KRYS's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Krystal Biotech, Inc.'s net income?

Krystal Biotech, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Krystal Biotech, Inc. generate?

Free cash flow shows how much cash Krystal Biotech, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Krystal Biotech, Inc. have?

Cash and debt help frame KRYS's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.